Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2011 1
2012 1
2014 1
2015 2
2016 2
2017 4
2018 3
2020 6
2021 4
2022 5
2023 1
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J, Aupérin A, Fayette J, Saada-Bouzid E, Lafond C, Taberna M, Geoffrois L, Martin L, Capitain O, Cupissol D, Castanie H, Vansteene D, Schafhausen P, Johnson A, Even C, Sire C, Duplomb S, Evrard C, Delord JP, Laguerre B, Zanetta S, Chevassus-Clément C, Fraslin A, Louat F, Sinigaglia L, Keilholz U, Bourhis J, Mesia R; GORTEC; AIO; TTCC, and UniCancer Head and Neck groups. Guigay J, et al. Lancet Oncol. 2021 Apr;22(4):463-475. doi: 10.1016/S1470-2045(20)30755-5. Epub 2021 Mar 5. Lancet Oncol. 2021. PMID: 33684370 Clinical Trial.
Targeted Therapy of Head and Neck Cancer.
Rieke DT, Klinghammer K, Keilholz U. Rieke DT, et al. Among authors: klinghammer k. Oncol Res Treat. 2016;39(12):780-786. doi: 10.1159/000452432. Epub 2016 Nov 22. Oncol Res Treat. 2016. PMID: 27889751 Review.
Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC.
Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, Treue D, Stenzinger A, Glimm H, Fröhling S, Kindler T, Brandts CH, Schulze-Osthoff K, Weichert W, Tinhofer I, Klauschen F, Keilholz U, Beule D, Rieke DT. Messerschmidt C, et al. Among authors: klinghammer k. Int J Cancer. 2020 Oct 15;147(8):2293-2302. doi: 10.1002/ijc.33123. Epub 2020 Jun 18. Int J Cancer. 2020. PMID: 32468570 Free article.
Animal models for personalized treatment options.
Fichtner I, Klinghammer K, Behrens D, Flechsig S, Rolff J, Becker M, Wulf-Goldenberg A, Stecklum M, Rivera M, Brzezicha B, Jandrig B, Hoffmann J. Fichtner I, et al. Among authors: klinghammer k. Int J Clin Pharmacol Ther. 2017 Aug;55(8):698-700. doi: 10.5414/CPXCES15EA09. Int J Clin Pharmacol Ther. 2017. PMID: 28696202 No abstract available.
Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility study.
Leyvraz S, Konietschke F, Peuker C, Schütte M, Kessler T, Ochsenreither S, Ditzhaus M, Sprünken ED, Dörpholz G, Lamping M, Rieke DT, Klinghammer K, Burock S, Ulrich C, Poch G, Schäfer R, Klauschen F, Joussen A, Yaspo ML, Keilholz U. Leyvraz S, et al. Among authors: klinghammer k. Eur J Cancer. 2022 Jul;169:146-155. doi: 10.1016/j.ejca.2022.04.004. Epub 2022 May 12. Eur J Cancer. 2022. PMID: 35569281
31 results